Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027

Sellas Life Sciences (SLS) reported that its experimental cancer vaccine, GPS, met its primary goal in a Phase 3 trial, reducing the risk of death by 41% in AML patients. The trial showed a median overall survival of 24 months vs. 14.7 months for the control group. The company plans to file for FDA approval in the first half of 2027. SLS shares rose 7.1% pre-market before trading was halted.

Original reporting
Published Nov 17, 2026, 12:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027 — source image
Decision brief

The 30-second read

$SLSBullishHigh
01

Why it matters

Pivotal Phase 3 success with statistically significant overall survival improvement and a stated FDA engagement and BLA filing window are likely to shift approval-probability expectations and near-to-medium-term valuation for SLS.

02

Market read

Traders can reprice SLS on the combination of a positive pivotal OS readout and a concrete regulatory timeline, with the next decision point being FDA discussions and subsequent BLA documentation.

03

What to watch

The article does not quantify magnitude of adverse events beyond 'mild/moderate' injection-site reactions, and it does not specify how BAT was defined or how cross-over was handled, both of which can matter for FDA review.

Relevance 9/10Novelty 9/10Timing: pre-market today, with trading halted after the announcement

Background

Sellas is developing Galinpepimut-S (GPS), a WT1-targeted cancer vaccine, as maintenance therapy for AML patients in second or later remission who cannot undergo stem cell transplant.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

Sellas reported Phase 3 Regal pivotal results for Galinpepimut-S in AML, cutting death risk by 41% and planning an FDA BLA filing in 1H 2027.

Expected impact

Likely upward pressure as traders price in accelerated regulatory momentum and improved probability of approval, tempered by remaining clinical and FDA-path uncertainty.

Evidence & confidence

The article discloses primary Phase 3 success metrics (hazard ratio, p-value, OS improvement) and a concrete next catalyst (FDA meeting and BLA filing timing).

Market effects

Strengthens sentiment for AML immunotherapy/vaccine approaches and can lift peer attention to WT1-targeting strategies and maintenance-therapy trial designs.

Primarily US biotech sentiment, with potential spillover to Nasdaq small-cap biotech liquidity and clinical-trial momentum trades.

Limited direct global macro impact, but can influence international biotech investors tracking US FDA accelerated-approval pathways.

Counterpoint

Even with positive Phase 3 OS, accelerated filing strategies can face FDA scrutiny on endpoints, patient selection, and confirmatory requirements, which may cap upside until additional details emerge.

Key entities

  • Sellas Life Sciences

    Reported pivotal Phase 3 Regal trial results for Galinpepimut-S in AML and outlined FDA accelerated filing preparations for 1H 2027.

  • Galinpepimut-S (GPS)

    Experimental cancer vaccine targeting WT1, evaluated as AML maintenance therapy.

  • U.S. Food and Drug Administration (FDA)

    Planned engagement to discuss accelerated filing strategy and BLA submission timing.

Related articles

$SLSHighAI 9/10

SELLAS Life Sciences stock soars 240% on positive cancer trial

SELLAS Life Sciences (NASDAQ:SLS) shares rose 240% after reporting positive Phase 3 trial results for its cancer vaccine, GPS. The trial met its primary endpoint, showing a 41% reduction in death risk and improved median survival. The company plans to discuss an accelerated FDA filing strategy. GPS was well-tolerated with mild to moderate side effects.

$SLSMedAI 8/10

Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial

SELLAS Life Sciences (SLS) reported that its cancer vaccine, galinpepimut-S, met the primary survival endpoint in a Phase 3 trial for acute myeloid leukemia. The vaccine reduced death risk by 41% compared to standard treatment, with median survival of 24 months versus 14.7 months. The company plans to discuss FDA filing strategy in 2027. SLS shares rose 7.10% in pre-market trading.

$SLSHighAI 9/10

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Ov

SELLAS Life Sciences (NASDAQ: SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, GPS, showing a 41% reduction in death risk and median OS of 24.0 months vs. 14.7 months for standard treatment. The company plans to meet with the FDA to discuss regulatory path. GPS was well-tolerated with no new safety signals. SELLAS will host a webcast to discuss results and next steps.

$SLSMedAI 8/10

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a…

SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid

$NVDAMed

Stocks making the biggest moves premarket: Disney, Home Depot, Nvidia & more

Coherent, Applied Optoelectronics, and Lumentum shares rose 11%, 8.6%, and 5.6% respectively, following a Reuters report on potential U.S. restrictions on Chinese data center equipment. Sellas Life Sciences shares gained over 7% after positive trial results for its cancer vaccine. Nvidia shares rose 1% ahead of earnings, despite a 25% stake reduction in Intel. Home Depot shares fell 2% with a CEO transition.

$SLSHighAI 8/10

SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too

BlackRock and a Vanguard unit added SLS, IBRX, IOVA, MRK, and LLY to their Q3 buy lists. Lilly reported strong sales from diabetes, obesity, and cancer drugs. Sellas (SLS) awaits Phase 3 trial results for its AML treatment. ImmunityBio (IBRX) plans expanded FDA approval for Anktiva. Iovance (IOVA) saw 77% YoY sales growth for Amtagvi and is testing it with Merck's (MRK) Keytruda. Retail sentiment varies across stocks.